Abstract: A herbal extract for anemia is obtained by a process including steps of drying, by providing a herbal material comprising dry mulberry and dry Acanthopanax senticosus in a weight ratio of 2:1 to 1:2, with the water content of the herbal material lower than 10%; extracting, by soaking the herbal material into a solvent to obtain a liquid extract, with the weight ratio between the herbal material and the solvent being 1:10 to 1:5; and condensation, by condensing the liquid extract to obtain a herbal extract.

Abstract: In the present invention, a ginger extract for inhibiting the fat-storage function of adipocytes and a medication thereof is disclosed, wherein the ginger extract is obtained form Alpinia galangal and Zingiber zerumbet.

Abstract: A herbal extract for anemia is obtained by a process including steps of drying, by providing a herbal material comprising dry mulberry and dry Acanthopanax senticosus in a weight ratio of 2:1 to 1:2, with the water content of the herbal material lower than 10%; extracting, by soaking the herbal material into a solvent to obtain a liquid extract, with the weight ratio between the herbal material and the solvent being 1:10 to 1:5; and condensation, by condensing the liquid extract to obtain a herbal extract.

Abstract: A manufacture method of microcapsule, comprises a step of extraction, by extracting active substance from a sample of Chinese angelica and obtaining an extract; a step of encapsulation, by encapsulating the extract with a covering, wherein the extract and the covering are mixed and co-dropped in a solidified solution for solidifying the covering, and the extract is encapsulated in the solidified covering to obtain a microcapsule; and a step of drying, by drying and finalizing the microcapsule.

Abstract: Compounds of general Formula I in which the substituents of R.sub.1 -R.sub.7 are hydrogen, hydroxy group, C.sub.1-6 alkyl group, C.sub.1-6 alkoxy group, or epoxypropoxy, but at the most, six of the substituents can simultaneously be hydrogen, methoxy group, or hydroxy group, or epoxypropoxy group for activity against hepatoma. There are also described processes for the preparation of the novel compounds and useful intermediates. Substitute benzophenones are described.

Abstract: Compounds of general Formula I in which the substituents of R.sub.1 -R.sub.7 are hydrogen, hydroxy group, C.sub.1-6 alkyl group, C.sub.1-6 alkoxy group, or epoxypropoxy, but at the most, six of the substituents can simultaneously be hydrogen, methoxy group, or hydroxy group, or epoxypropoxy group for activity against hepatoma. There are also described processes for the preparation of the novel compounds and useful intermediates. Substitute benzophenones are described.

Abstract: A compound, and salts thereof, represented by either formula I or formula II below:(1) Formula I: ##STR1## wherein substituents R.sub.1 -R.sub.7 can be, independently, hydrogen, hydroxy group, C.sub.1-6 alkyl(oxy) group, acetyl ester, or C.sub.1-12 alkyl propanolamine; at least three but no more than four of the substituents are alkyl(oxy) group, hydroxyl group or acetyl ester; no more than one of the substituents can be C.sub.1-12 alkyl propanolamines; R.sub.1, R.sub.3, R.sub.7 cnnnot all be hydroxy groups at the same time; and R.sub.6 is either an hydroxy group or an oxygen-containing glucose.(2) Formula II: ##STR2## wherein substituents R.sub.1 -R.sub.9 can be, indenpendently, hydrogen, hydroxy group and C.sub.1-6 alkyl(oxy) group; and no more then four of the substituents can be methoxy group, hydroxy group, or acetyl ester. These compounds were tested to be capable of inhibiting platelet aggregation, atrioventricular conduction, and calcium influx in myocardiac cells.